Clinical trials are experiments designed to test the safety and efficacy of new treatments or interventions in a controlled setting. The results of these trials are used to make decisions about whether or not to approve new drugs or treatments for use in the general population.
However, it’s important to recognize that the results of clinical trials may have limitations when it comes to their generalizability to the larger population. This is because clinical trials are typically conducted under controlled conditions, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.
Some of the limitations of clinical trial results in terms of generalizability to the larger population include:
Limited patient population: Clinical trials often have strict inclusion and exclusion criteria, which can limit the types of patients who are eligible to participate. This means that the results may not be generalizable to patients who do not meet these criteria.
Short follow-up time: Clinical trials are often conducted over a relatively short period of time, which may not be long enough to capture the long-term effects of the treatment or intervention.
Controlled setting: Clinical trials are conducted in a controlled setting, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.
Selective reporting [Controversial]: Clinical trial results may be subject to selective reporting, where only the most favorable outcomes are reported, while negative results are suppressed.
Real-world evidence (RWE) refers to data collected outside of clinical trials, such as data from electronic health records, insurance claims, and patient registries. RWE can provide important insights into how treatments or interventions work in real-world settings, and can help to address some of the limitations of clinical trial results in terms of generalizability.
However, it’s important to recognize that RWE also has its own limitations, such as the potential for confounding and bias, as well as issues related to data quality and completeness. Therefore, it’s important to carefully consider the limitations and potential biases of both clinical trial results and real-world evidence when making decisions about treatments or interventions for the larger population.
Share this story...
Real World Evidence (RWE) 101 – NICE Real World Evidence Framework
RWE 101 - NICE Real World Evidence Framework The UK's National Institute for Health and Care Excellence (NICE) has developed a Real World Evidence (RWE) Framework to help evaluate [...]
Real World Evidence (RWE) 101 – The Role of RWE in Health Technology Assessments (HTAs)
RWE 101 - The Role of RWE in Health Technology Assessments (HTAs) Real-world evidence (RWE) is becoming increasingly important in the context of health technology assessment (HTA), which is [...]
Real World Evidence (RWE) 101 – Verifying the Source of Data (Not to be Confused with Source Data Verification…Yup! Confusing!)
RWE 101 - Verifying the Source of Data (Not to be Confused with Source Data Verification...Yup! Confusing!) Verifying the source of data is critical in the context of real [...]
Real World Evidence (RWE) 101 – Challenges in RWE Generation (Regulatory Grade RWE?)
RWE 101 - Challenges in RWE Generation (Regulatory Grade RWE?) Real-world evidence (RWE) refers to data derived from real-world sources such as electronic health records, claims data, and patient-generated [...]
Real World Evidence (RWE) 101 – Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations
RWE 101 - Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations Real-world evidence (RWE) studies include observational studies that uses data collected in real-world settings to [...]
Real World Evidence (RWE) 101 – Acknowledgement of the Limitations of Clinical Trials and RWE Studies
RWE 101 - Acknowledgement of the Limitations of Clinical Trials and RWE Studies Clinical trials are experiments designed to test the safety and efficacy of new treatments or [...]







